Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
89Zr-DFOsq-bisPSMA
- Development stage
- Preclinical
- Lead developer
- Telix Pharmaceuticals
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals, Small Molecules
- Administration
- Intravenous
01
Overview
89Zr-DFOsq-bisPSMA (also known as [89Zr]Zr-DFOSq-bisPhPSMA) is a bivalent, small-molecule positron emission tomography (PET) imaging tracer designed for the diagnostic detection of prostate-specific membrane antigen (PSMA)-expressing prostate cancer. It consists of a bivalent lysine-ureido-glutamate PSMA-targeting motif conjugated to a squaramide ester derivative of desferrioxamine B (DFOSq) chelator, which is radiolabeled with the positron-emitting radionuclide zirconium-89 (89Zr). The bivalent design enhances binding affinity and tumor retention compared to monovalent analogs, while the use of zirconium-89, with its physical half-life of 78.4 hours, allows for delayed PET imaging time points to optimize tumor-to-background contrast. The tracer was developed by the University of Melbourne in collaboration with Telix Pharmaceuticals, Peter MacCallum Cancer Centre, Austin Health, and Cyclotek.
- Other names
- 89Zr-DFOSq-bisPSMA89Zr-DFOSq-bisPhPSMA[89Zr]Zr-DFOSq-bisPSMA[89Zr]Zr-DFOSq-bisPhPSMA[89Zr]ZrDFOSq-bisPhPSMA
02
Targets
PSMA (Prostate-specific membrane antigen)
Beyond the preview
Go deeper on 89Zr-DFOsq-bisPSMA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 89Zr-DFOsq-bisPSMA.